PRMT7 and CD8 T cells: releasing an internal immune brake

PRMT7 and CD8 T cells appear to have an unusual relationship: the protein acts as an internal restraint that prevents antitumor T cells from fully engaging their activation program. When researchers removed PRMT7 genetically or induced the cell to destroy the protein, the T cells proliferated more strongly and became more effective killers of tumor cells.

CD8+ T lymphocytes are among the immune system's main weapons against cancer. They can recognize abnormal cells and kill them directly. Several forms of adoptive cell therapy exploit this ability by collecting T cells, expanding or modifying them outside the body, and then returning them to the patient.

Producing large numbers of T cells, however, is only part of the challenge. The expanded cells also need to retain strong effector function. Understanding the molecular brakes that limit both proliferation and killing capacity could therefore provide new ways to improve cell-based immunotherapies.

A protein that restrains an activation pathway

The study focused on PRMT7, an enzyme that can modify proteins by adding a methyl group to the amino acid arginine. In this study, however, its most interesting effect appeared to involve a role that was not simply explained by its catalytic activity.

The researchers selectively deleted Prmt7 in mouse T cells. T-cell development remained largely intact, but changes emerged particularly within the CD8+ population. In normal cells, Prmt7 messenger RNA was about four times more abundant in CD8+ than in CD4+ T cells.

Without Prmt7, CD8+ T cells shifted toward a more effector-like state. They proliferated more, produced more interferon-gamma and showed greater cytotoxic activity against target cells.

The researchers traced much of this effect to NF-κB, one of the cell's major signaling systems for immune activation. A central component of this pathway, the protein RelA, must enter the nucleus after activation to switch on genes involved in the immune response.

PRMT7 associated with RelA and restricted its movement into the nucleus. Removing PRMT7 loosened that restraint, increasing NF-κB activity and strengthening the transcriptional program associated with CD8+ T-cell proliferation and effector function.

Destroying the protein instead of deleting the gene

Genetic deletion is a powerful way to establish mechanism, but it is not necessarily a practical way to prepare therapeutic T cells. The authors therefore developed MS54, a molecule designed to make the cell eliminate PRMT7 itself.

MS54 is a PROTAC degrader. In simplified terms, a PROTAC works like a molecular connector: one end binds the target protein, while the other recruits the cell's protein-disposal machinery. The target is then marked for destruction and degraded.

Mouse cytotoxic T cells treated with MS54 reproduced several features of Prmt7-deficient cells, including stronger NF-κB signaling and increased indicators of effector activity.

The researchers next tested these cells in a syngeneic mouse model of melanoma. Antitumor CD8+ T cells were treated with MS54 before adoptive transfer. The treated cells produced better tumor control than the corresponding control cells.

The effect was not restricted to mouse T cells. In experiments with human cytotoxic T lymphocytes, MS54 increased proliferation, expression of the activation markers CD69 and CD137, interferon-gamma production and cytotoxicity against melanoma cells.

A preclinical strategy, not yet a treatment

The study makes two related points. First, PRMT7 acts as a previously underappreciated molecular restraint on antitumor CD8+ T-cell activity. Second, that restraint can be removed not only through genetic manipulation but also by inducing degradation of the PRMT7 protein.

The translational gap remains substantial. Tumor control was demonstrated in a mouse melanoma model, while the experiments with human T cells were performed outside the body. MS54 remains an experimental degrader, and its safety and therapeutic efficacy have not been established in patients.

The study therefore does not demonstrate a new treatment for melanoma. Instead, it suggests a different way of thinking about adoptive cell therapy: T cells might potentially be made more effective during their preparation by temporarily removing one of their own molecular brakes before they are transferred back into the body.